Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

SevasemtenEDG-7500Positive

AI Analysis

Summary

Edgewise Therapeutics completed the sale of Sevasemten for up to $2.65 billion, receiving $1.55 billion upfront and becoming eligible for up to $1.1 billion in regulatory and commercial milestones. The transaction strengthens Edgewise's balance sheet and refocuses the company on its cardiovascular pipeline development.

Outcome Details

Sale of Sevasemten asset

Importance:7/10

Sentiment:

0.70

asset salecash proceedscardiovascular focusbalance sheet strengtheningmilestone payments

Related Companies

$EWTX

Read the original article

Published by PR Newswire Biotech on July 13, 2026 12:30 PM

Read Original